Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 15/20 | 0.62 |
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 0.62 |
| ▸ | DRD3 | P35462 | 8/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5906537 | 1.00 | HTR1A (0.62) | HTR1ADRD2DRD3 | |
| SCHEMBL1752535 | 0.89 | HTR1A (0.71) | HTR1ADRD2DRD3 | |
| SCHEMBL5141708 | 0.89 | HTR1A (0.71) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL1229224 | 0.88 | HTR1A (0.82) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL7046470 | 0.88 | HTR1A (0.82) | HTR1ADRD2DRD3 | |
| Malic Acid SCHEMBL6399751 | 0.83 | HTR1A (0.55) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL30503038 | 0.77 | HTR1A (1.00) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL29518262 | 0.77 | HTR1A (1.00) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL154412 | 0.77 | HTR1A (1.00) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL6269816 | 0.77 | HTR1A (1.00) | HTR1ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060040929-A1 | (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione and method of preparation thereof | MCCALL ROBERT B | 2006-02-23 | — | — | US | claimed |
| US-6921771-B2 | Method of treating sexual disturbances | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-26 | — | — | US | claimed |
| US-6903127-B2 | Method of treating sexual disturbances | PHARMACIA & UPJOHN COMPANY (US) | 2005-06-07 | — | — | US | claimed |
| US-6890945-B2 | Method of treating sexual disturbances | PHARMACIA & UPJOHN COMPANY (US) | 2005-05-10 | — | — | US | claimed |
| US-6841557-B2 | Compounds for the treatment of addictive disorders | PHARMACIA & UPJOHN (US) | 2005-01-11 | — | — | US | claimed |
| US-20040266812-A1 | (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione | PHARMACIA & UPJOHN COMPANY | 2004-12-30 | — | — | US | claimed |
| US-20040214826-A1 | Method of treating sexual disturbances | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | claimed |
| US-20040214825-A1 | treating sexual disorders using (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | claimed |
| US-20040214824-A1 | Method of treating sexual disturbances | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | claimed |
| US-6809112-B2 | ADMINISTERING A SEXUALLY THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND HAVING THE FORMULA LIKE (5R)-5-(METHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLINE-2(1H)-THIONE | PHARMACIA & UPJOHN COMPANY | 2004-10-26 | — | — | US | claimed |
| EP-1274430-A2 | COMPOUNDS FOR TREATING FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-15 | — | — | EP | claimed |
| US-20020143010-A1 | Compounds for treating fibromyalgia and chronic fatigue syndrome | MCCALL ROBERT B (US) | 2002-10-03 | — | — | US | claimed |
| US-20020137763-A1 | (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione | PHARMACIA & UPJOHN COMPANY | 2002-09-26 | — | — | US | claimed |
| US-6448258-B2 | HETEROCYCLIC AMINE COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2002-09-10 | — | — | US | claimed |
| US-20020107257-A1 | Treatments for restless legs syndrome | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| WO-2002036123-A2 | NEW TREATMENTS FOR RESTLESS LEGS SYNDROME | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-10 | — | — | WO | claimed |
| US-20020049206-A1 | Compounds for the treatment of addictive disorders | PHARMACIA & UPJOHN (A DELAWARE CORPORATION) | 2002-04-25 | — | — | US | claimed |
| US-20020004510-A1 | Compounds for treating fibromyalgia and chronic fatigue syndrome | PHARMACIA & UPJOHN COMPANY | 2002-01-10 | — | — | US | claimed |
| WO-2001083483-A1 | (5R)-(METHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZO[4,5,1-ij]QUINOLINE-2(1H)-THIONE | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001081343-A2 | COMPOUNDS FOR TREATING FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049206-A1 | Compounds for the treatment of addictive disorders | OPRK1, SLC6A3, TACR2 | HTR1A 126/4885DRD2 11/4885DRD3 26/4885 |
| US-20040214824-A1 | Method of treating sexual disturbances | CYP19A1, CYP17A1, CYP21A2 | HTR1A 43/4885DRD2 332/4885DRD3 295/4885 |
| US-20040214825-A1 | treating sexual disorders using (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione | SULT1A1, CYP19A1, SHBG | HTR1A 46/4885DRD2 302/4885DRD3 496/4885 |
| US-20020004510-A1 | Compounds for treating fibromyalgia and chronic fatigue syndrome | GRK5, GRK4, GPR35 | HTR1A 82/4885DRD2 1359/4885DRD3 1356/4885 |
| US-20040214826-A1 | Method of treating sexual disturbances | CYP19A1, CYP17A1, CYP21A2 | HTR1A 43/4885DRD2 332/4885DRD3 295/4885 |
| US-20020137763-A1 | (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione | QDPR, UGT1A4, CYP3A5 | HTR1A 117/4885DRD2 1062/4885DRD3 1812/4885 |
| US-20020143010-A1 | Compounds for treating fibromyalgia and chronic fatigue syndrome | GRK5, GRK4, GPR35 | HTR1A 82/4885DRD2 1359/4885DRD3 1356/4885 |
| US-20020107257-A1 | Treatments for restless legs syndrome | HCRTR2, PNMT, HCRTR1 | HTR1A 34/4885DRD2 189/4885DRD3 329/4885 |
| US-20060040929-A1 | (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione and method of preparation thereof | CYP3A5, UGT1A1, SULT1A1 | HTR1A 81/4885DRD2 446/4885DRD3 822/4885 |
| US-20040266812-A1 | (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione | CYP3A5, UGT1A4, QDPR | HTR1A 103/4885DRD2 1113/4885DRD3 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.